МРТ корреляции депрессии и тревоги при множественном склерозе.

1. Introduction

Multiple sclerosis (MS) is a chronic inflammatory condition that causes inflammation, demyelination, and neurodegeneration of the central nervous system (CNS). Some patients experience remission, during which remyelination and neurogenesis occur in the CNS, leading to a partial recovery. The chronic phase of MS is often associated with permanent neurological dysfunction, primarily caused by axonal degeneration [ 1 , 2 ].

The etiology of multiple sclerosis remains incompletely understood. Current hypotheses emphasize the complex interactions between genetic susceptibility and environmental factors, including autoimmune mechanisms, viral infections, and vitamin D deficiency. Recent evidence has further strengthened the association between Epstein–Barr virus infection and the subsequent development of MS [ 3 ].

Histopathologically, MS is characterized by perivascular lymphocytic and macrophage infiltration accompanied by demyelination of nerve fibers within the brain, spinal cord, and cranial nerves (8). Because lesions may involve multiple regions of the central nervous system, their clinical presentations are highly heterogeneous. MRI remains the reference imaging modality for the detection and longitudinal monitoring of MS-related lesions. Typical sites of involvement include the periventricular white matter, callososeptal interface along the inferior surface of the corpus callosum, subcortical U-fibers, brainstem, and spinal cord [ 4 , 5 ].

Although conventional MRI is highly sensitive in detecting lesions associated with multiple sclerosis, it has limited specificity for characterizing lesion severity and underlying pathological processes. It also does not capture the full range of imaging biomarkers required for robust clinical assessment and prognostic stratification of patients. Histopathological–imaging correlation studies have shown that conventional MRI may fail to detect persistent microscopic abnormalities within the normal-appearing white matter, despite the presence of established demyelination, gliosis, axonal injury, or neurodegeneration [ 6 ]. More advanced MRI approaches, such as higher-field imaging at 3 T and 7 T [ 7 ], as well as quantitative and functional techniques, might allow more accurate characterization of MS-related pathology. These methods may improve the correlation between imaging findings and clinical status, diagnostic specificity for underlying tissue damage, and assessment of processes involved in the accumulation of subsequent disability.

MRI studies of sodium have shown that patients with MS have increased total brain tissue sodium (23Na) concentration. This finding may be linked to cell homeostasis and metabolic integrity in both focal lesions and normal-appearing white and gray matter [ 7 ]. Ultra-high-field MRI at 7 T could provide additional information on sodium distribution, including the intracellular sodium component, which has been suggested as a potential biomarker of functional tissue impairment. Transmembrane sodium exchange is a determinant of intracellular sodium concentration and may provide indirect information on cellular metabolism and membrane integrity. In addition, the higher signal-to-noise and contrast-to-noise ratios achieved at 7 T enable improved visualization of anatomical structures and pathological lesions with higher spatial resolution [ 7 , 8 ].

Acute demyelinating lesions may exhibit restricted diffusion on diffusion-weighted imaging. This restricted diffusion may be peripheral or ring-like, corresponding to the actively expanding edge of the lesion. Diffusion restriction is not a uniform feature of acute MS lesions. Following gadolinium administration, active demyelinating plaques may exhibit nodular, ring-like, or incomplete ring enhancement on T1-weighted images [ 4 , 9 ]. Enhancement generally persists for approximately 4–8 weeks and reflects the transient disruption of the blood–brain barrier during active inflammation. Because MS lesions develop at different time points, enhancing and non-enhancing plaques may coexist, providing imaging evidence of dissemination over time [ 10 ].

The clinical course and prognosis of MS are heterogeneous and depend on several factors, including the age at onset, presenting symptoms, and disease phenotype. Younger age, optic neuritis or sensory symptoms at onset, and a relapsing–remitting course have traditionally been associated with a more favorable prognosis. Although a substantial proportion of patients remain only mildly or moderately affected, others experience a prolonged disease course, characterized by the progressive accumulation of neurological deficits. Advanced disease may be associated with marked physical disability and cognitive impairment [ 5 , 11 ]. In individuals older than 45 years, periventricular white matter lesions require judicious interpretation because chronic small-vessel ischemic changes may mimic demyelinating plaques, thereby increasing the risk of misdiagnosis [ 12 ].

Compared with the 2017 McDonald criteria, the 2024 revision expands dissemination in space by including the optic nerve as a fifth anatomical location, accepts the kappa free-light-chain index as an alternative to CSF oligoclonal bands, and incorporates the central vein sign and paramagnetic rim lesions as supportive imaging biomarkers. The revised framework also reduces the obligatory role of dissemination in time in selected diagnostic pathways and introduces more explicit recommendations for radiologically isolated syndrome, progressive disease, pediatric presentations, and older patients with potential vascular mimics [ 10 ].

Normal-appearing white matter (NAWM) describes noninfarcted white matter that appears unaffected on conventional MRI, but may still contain diffuse microscopic abnormalities, including gliosis, axonal injury, demyelination, and metabolic disturbance. Proton MR spectroscopy may provide additional information regarding these changes. Increased myo-inositol levels may indicate glial proliferation, decreased N-acetylaspartate (NAA) may reflect axonal or neuronal dysfunction, while increased glutamate may be linked to excitotoxic injury. During the acute inflammatory phase, increased concentrations of choline, creatine, myo-inositol, and glutamate may be observed in the brain, along with decreased NAA. In chronic diseases, persistent elevation of myo-inositol and reduction in N-acetylaspartate are more commonly reported, consistent with ongoing gliosis and axonal loss [ 13 ]. In recent years, a better insight into the pathophysiology of MS has contributed to the development of innovative treatment strategies.

MS impacts more than just movement, sensorium, vision, and cognition. Neuropsychiatric symptom studies have provided new insights into the biology of MS, and provided new therapeutic targets to improve MS patients’ care [ 14 , 15 ]. Anxiety, depression, affective disturbances, hypomanic symptoms and cognitive impairment are the most commonly reported conditions, substantially contributing to the disease burden and reduced quality of life [ 15 , 16 , 17 , 18 , 19 ]. Beyond neurological disability, psychiatric symptoms are increasingly recognized as part of a complex and multidimensional disease burden in patients with MS. Psychiatric manifestations are often associated with broader systemic and functional impairments. Depression, anxiety, alcohol abuse, cognitive decline, and chronic medical comorbidities are all linked through interconnected biopsychosocial and neuroendocrine pathways [ 20 , 21 , 22 , 23 ]. Multidisciplinary and patient-centered approaches that integrate psychological, social, and somatic dimensions, especially in vulnerable populations with cognitive impairment, chronic disease burden, or substance-related disorders [ 24 , 25 ].

Psychiatric symptoms are more commonly encountered in relapsing-remitting multiple sclerosis (RRMS) and are now increasingly recognized as an integral component of MS rather than merely a secondary psychological reaction to physical disability [ 26 , 27 , 28 ]. Emotional instability and introverted personality traits may increase vulnerability to negative affectivity. Psychosocial distress, psychological stress, and persistent negative mood were associated with more frequent relapses than those in patients experiencing a more stable remitting course [ 29 , 30 , 31 ]. Mood disorders in multiple sclerosis are thought to have multiple causes, including a reactive component and potentially a distinct neuropathological process, which tends to be very common during the early stages of MS [ 32 ]. “Pathological hidden changes” such as cognitive impairment, anxiety, depression, and migraines were observed many years prior to the onset of MS and were termed prodromal symptoms [ 33 , 34 , 35 , 36 , 37 ]. Structural MRI may be useful for assessing lesion location and volume, white matter lesion burden and atrophy [ 38 ].

This review examines the most relevant MRI findings and ongoing controversies in the current literature to provide a comprehensive understanding of multiple sclerosis.

2. Materials and Methods

This study was designed as a structured comprehensive review of the available literature on MRI correlates of depression and anxiety in multiple sclerosis. A literature search was conducted from May 2014 to May 2026 in the PubMed, Web of Science, and Scopus databases, using systematic review methodology, conducted and reported in compliance with the PRISMA 2020 Statement [ 39 ]. The following Medical Subject Headings (MeSH) terms and combinations of the following key words were used: for magnetic resonance imaging—“MRI”, “MR”, “structural MRI”, “fMRI”, “DTI”, “structural connectivity” “lesion load”, “gray matter atrophy”, “white matter”, “hippocampus”, “amygdala”, “infratentorial” and for coexisting neuropsychiatric conditions—“depression”, “anxiety”, “neuropsychiatric disorders” along with “multiple sclerosis”, “MS”, “relapsing-remitting MS”, “secondary progressive MS”. To ensure a more comprehensive search, the reference lists of all eligible studies were manually reviewed for additional relevant records. Gray literature sources were not included in the search strategy. The research addressed both qualitative and quantitative studies. The research question was structured according to the PICO framework, reported in Appendix A .

2.1. Inclusion/Exclusion Criteria

Primary studies with patients with confirmed multiple sclerosis aged >18 years old, who underwent conventional MRI, functional and/or diffusion MRI scans, and were evaluated using validated psychometric tests for depression and/or anxiety or established diagnostic criteria were included. Cross-sectional, cohort, randomized controlled trials, and quasi-experimental studies on patients with multiple sclerosis with depression and/or anxiety were included.

Criteria for exclusion were non-English articles, review articles, abstracts, editorials, conference papers, meetings, letters, errata, case reports, pediatric studies, and non-human studies.

2.2. Data Extraction, Synthesis and Quality Assessment

Two reviewers (P.L.S. and M-C.S-D.) independently screened the titles and abstracts of all identified records according to the inclusion and exclusion criteria to minimize bias in the selection process. Full texts were evaluated if eligibility could not be determined by title/abstract. Duplicate records were removed from both within and across databases. Studies without specific MRI correlations, or studies where patients with MS were only a small subgroup within a heterogeneous cohort, and no separate analysis or extractable data were provided, were excluded. The risk of bias assessment was conducted based on the alignment between each study’s methodological approach and research question, the appropriateness of data collection methods and reports of data analysis, consistency between conclusions and analysis, and the presence of ethical approval. Disagreements were resolved through discussion. The following variables were extracted: study design, sample size, psychometric assessment tools, MRI modality and sequences, assessed brain regions, lesion burden measures (if available), volumetric data, and reported MRI–psychopathological correlations. The evidence was synthesized as a narrative review, due to significant heterogeneity that may prevent pooled data. The review protocol was not prospectively registered in PROSPERO or in another publicly accessible systematic review registry.

3. Results

The database search retrieved 2626 records. After removing duplicates and excluding non-original study designs, non-peer-reviewed or non-full-text materials, case reports, pediatric populations, and non-human studies, 523 records were assessed by title and abstract. Of the 120 reports, we excluded 18 records with no clearly specified psychometric tool, 27 records where patients with MS were only a small subgroup within a heterogeneous cohort, and 48 records with no specific MRI-derived outcomes. Twenty-seven studies met the inclusion criteria and were included in the review ( Figure 1 ).

3.1. Depression

3.1.1. Epidemiology and Clinical Impact

Among all psychiatric comorbidities in MS, depression is the most prevalent and extensively studied condition. It was three to five times more frequent than in the general population [ 67 ], underscoring the disproportionate mental health burden experienced by individuals with MS. It ranged from 18.5% [ 68 ] to 58.9% [ 69 ] among PwMS, reflecting the heterogeneity in research populations, diagnostic methods, and assessment tools. According to epidemiological findings, the rates of depression in PwMS vary significantly across Europe. A study conducted in Spain found an overall prevalence of 44%, yet there were marked differences by MS subtype—with a striking 88% in relapsing-remitting MS (RRMS), versus 12.2% in secondary progressive MS (SPMS) [ 70 ]. In England, a large cohort study reported that 21% of PwMS exhibited depression at baseline, in contrast to 9% of healthy controls [ 71 ]. Another multicenter German study identified at least minimal depressive symptoms in 32.8% of patients, with 16.1% with mild symptoms and 15.9% with severe depression [ 72 ].

Depressive symptoms were closely associated with inflammatory disease activity. Depression was more frequently observed in the relapsing phases of increased neuroinflammation, particularly during clinical relapses, and was more common in the early years following disease onset. This temporal association supported the hypothesis that inflammatory mechanisms, rather than psychosocial factors alone, contribute to a significant association in the development of depressive symptoms. With aging, depressive symptoms tend to decrease, as neurodegenerative processes becoming more prevalent, suggesting a change in the biological factors that affect mood regulation [ 73 ]. Recent research on metabolic and oxidative stress pathways provided a useful biological framework for understanding affective symptoms as multidimensional and not purely reactive manifestations of complex chronic disorders, highlighting the broader role of inflammation, endocrine imbalance, and oxidative injury [ 74 , 75 ].

Depression is considered a debilitating comorbidity and associated with decreased quality of life, disability progression, cognitive impairment, poor treatment adherence, and increased fatigue [ 76 ], even though fatigue is considered both a symptom and a complication of depression [ 73 ]. Emerging data also suggest that chronic stress, depression and alcohol-related behavioral disturbances influence complex neurobiological and inflammatory changes, including hypothalamic–pituitary–adrenal axis dysregulation, impaired healing, metabolic dysfunction and reduced functional outcomes [ 20 , 21 , 22 ].

Furthermore, it remains under-recognized and undertreated, with approximately 23–30% of cases going undiagnosed and 20–36% of diagnosed patients receiving insufficient treatment [ 77 ].

3.1.2. Imaging Findings

Structural MRI

Depressive symptoms were highly correlated with psychometric tests, lesion load on T2-weighted sequences, and globally reduced volume [ 48 , 51 ], compared to non-depressed patients. Depression was associated with structural GM abnormalities rather than WM lesion load [ 55 ]. It was linked to reduced cortical surface area and volume, especially in the frontal pole, pars orbitalis orbitofrontal cortex, and rostral and caudal segments of the middle frontal gyrus, and precentral and postcentral regions. Additional involvement was observed in the left temporal regions, such as the middle temporal, fusiform, and parahippocampal regions [ 55 ]. Reduced volumes were observed predominantly in the orbitofrontal cortex and pars orbitalis, along with the superior frontal cortex, rostral and caudal middle frontal gyri, and precentral and postcentral areas, right supramarginal and superior temporal regions, and left fusiform and inferior temporal cortices [ 50 , 55 ], highlighting frontal cortical thinning as the best predictor. Additionally, depression severity has been linked to reduced olfactory bulb volume in patients with progressive MS [ 53 ]. Cortical thickness was not significantly correlated with depression severity, suggesting that depression was more related to alterations in surface area and volume than to diffuse cortical thinning, and it also remained partly independent of WM lesion load [ 41 , 46 , 53 , 55 ]. Other recent studies highlighted that reduced gray matter volume in the right prefrontal cortex [ 78 ], and in the right dorsolateral and inferior frontal cortices (using voxel-based morphometry) [ 79 ] predicted subsequent worsening, or lack of improvement, in depressive symptoms.

A longitudinal study [ 78 ] demonstrated that increased volume loss of the left thalamus and right internal globus pallidus, and decreased GM volume in the right middle cingulate cortex and middle frontal gyrus were predictive of subsequent worsening of depressive and anhedonic symptomatology. Thalamic atrophy in both patient groups, compared to healthy controls, indicated this change is more correlated to MS-related neurodegeneration than a depression-specific process.

The limbic motivational basal ganglia circuit contains interconnected structures, including the mediodorsal thalamus and internal globus pallidus [ 80 ]. The globus pallidus is a key node in the dopaminergic reward-processing circuit [ 81 ], which can serve as a conceptual reference to contextually understand the association between its progressive atrophy and the longitudinal course of depressive symptoms. Structural degeneration of the globus pallidus compromises its ability to encode reward-related information in the brain. This leads to core depressive features such as apathy and anhedonia. From a clinical perspective, it was noteworthy that anhedonia linked to pallidal dysfunction may be, at least partially, reversible through dopaminergic modulation [ 78 ].

Progressive damage to subcortical motivational systems represented a risk factor for the development of depression in people with MS, whereas preserved prefrontal function may act as a protective or resilience factor [ 78 ].

Depression was correlated with infratentorial lesions [ 59 , 82 ] and was strongly correlated with damage to serotonergic and noradrenergic brainstem nuclei, the raphe nuclei, and the locus coeruleus, overlapping with neuropathological findings in Parkinson’s disease [ 83 , 84 ]. Depression was correlated with medial midbrain and medial pons lesions, but no association was observed with cerebellar lobule VIIA [ 59 ].

The association of depressive symptomatology in patients with RRMS to selective atrophy of posterior cerebellar structures, especially vermis Crus I, rather than white or gray matter lesion burden, supported a network-based model of affective dysfunction involving cerebello-limbic circuits was supported by the fact that was linked to [ 47 ].

A retrospective study by Hillyer et al. [ 60 ] found no significant association between depressive symptomatology and the presence, number, or volume of lesions within limbic system structures on 7T MRI. These results were consistent with previous limbic-focused research [ 56 , 85 ]. Notably, Berg et al. [ 85 ] reported that people with MS (PwMS) and depression exhibited an increased lesion burden in cortical projection regions linked to the limbic system (the temporal, frontal, and parietal lobes), while no corresponding increase was observed within the limbic system.

White matter lesions had similar patterns in patients with vascular depression, supporting the hypothesis of common underlying pathophysiological mechanisms contributing to secondary forms of depressive disorders [ 86 ].

Diffusion tensor imaging

Diffusion tensor imaging (DTI) is a new, non-invasive MRI method that allows assessment of the brain microstructure. Fractional anisotropy (FA) measures the extent of water movement in different directions within tissue. Lower FA values indicate white matter abnormalities caused by axonal damage. DTI provides enhanced specificity in the assessment of multiple sclerosis (MS) compared to conventional MRI because of the heterogeneous characteristics of its underlying pathology [ 87 ]. It enabled the characterization of tissue damage not only in overt white matter lesions, but also in normal-appearing white matter (NAWM) and gray matter (NAGM), as well as in the optic nerves and spinal cord. Changes such as lower FA and increased mean diffusivity may occur before visible lesions on conventional MRI [ 49 , 88 ].

Diffusion imaging studies demonstrated reduced FA within the NAWM in PwMS and depression, and increased mean diffusivity in the NAGM, particularly in the temporal lobes and inferior frontal regions. These modifications were associated with cortical atrophy in the bilateral frontal areas [ 49 , 89 , 90 , 91 ].

Baller et al. found a link between depression and MRI data, using lesion network mapping. Associations with occurrence and severity of depression were stronger for the lesion load within specific depression-associated white matter tract segments, compared to total lesion volume [ 40 ].

In PwMS, the development of depression was associated with disruption of the limbic-motor interface, and broader network disconnection, as demonstrated by alterations in the structural connectivity between the right hippocampus and amygdala, and frontal regions [ 56 , 91 ]. Some studies [ 48 , 56 ] highlighted alterations in structural network organization, specifically increased path length between the amygdala and hippocampus and the prefrontal cortex, associated with structural changes with decreased amygdalar volumes, suggesting impaired efficiency of information transfer across these regions. Previous studies showed that conscientiousness and WM pathology in MS were connected, with specific fronto-parietal networks being disrupted. These networks included structural connections linking the frontal, fronto-cingulate, frontoparietal, and basal ganglia gray matter (GM) regions [ 91 , 92 ]. Those regions were associated with executive control and the formation of associations between actions and rewards [ 93 ]. Given the well-established association between conscientiousness and depression, it was hypothesized that WM tract disruption within conscientiousness-associated frontoparietal networks (CFPN) may serve as a predictor of incident, clinically diagnosed depression over a 5-year period in PwMS [ 92 ]. In addition, van Geest et al. showed that depressed MS patients had reduced FA in the uncinate fasciculus [ 48 ], consistent with previous studies [ 49 ], where a significant reduction in the FA of the cingulum and fornix was additionally noted.

Functional MRI

Functional MRI (fMRI) in patients with MS and depression demonstrated impaired functional connectivity (FC) within reward circuits, fronto-limbic, and fronto-striatal networks, frequently indicating diminished connectivity between the prefrontal cortex and amygdala. These changes were linked to the severity of depression and brain inflammation, showing that depression related to MS was caused by brain damage (lesions and atrophy) rather than just a mental response to the disease, which was correlated with widespread network-level alterations [ 91 , 94 , 95 , 96 ].

Functional connectivity alterations are associated with reorganization of the brain network in response to MS-related damages, with increased compensatory connectivity [ 45 , 91 ].

The link between depressive symptoms and atypical connectivity was evident, particularly in the serotonergic and noradrenergic systems. The connectivity pattern involved the brainstem nuclei, cerebellum, and their projections to the limbic and frontal regions, pointing to a neurotransmitter-driven network mechanism underlying depression [ 45 ].

Resting-state fMRI analyses showed that changes in connectivity extend beyond the usual fronto-limbic circuits. They also include areas such as the cerebellum and hypothalamus, which are involved in regulating emotions and the autonomic nervous system, adding to the neurobiological understanding of depression in patients with MS [ 45 , 91 , 97 ].

Van Geest et al. showed that depressed MS patients had reduced functional connectivity between the amygdala and frontal regions. Disease duration, fractional anisotropy of the left uncinate fasciculus, and functional connectivity of the right amygdala accounted for 48% of the variance in depression severity [ 48 ].

3.2. Anxiety

3.2.1. Epidemiology and Clinical Impact

Anxiety is another prevalent psychiatric symptom in PwMS, with a prevalence varying from 19.3% [ 98 ] to 58% [ 99 , 100 ]. Anxiety was most frequently observed at the peri-diagnostic time [ 101 ], as well as during phases of clinical relapse, associated with neurological disability, uncertainty related to the course of the disease, treatment options, and quality of life disturbances [ 102 , 103 ]. At this stage, there may be increased emotional discomfort associated with adjustment to a newly diagnosed chronic neurological disorder. Anxiety negatively impacts the patient’s quality of life and can intensify pain and fatigue [ 104 ]. Anxiety was approached as a single psychopathological symptom, in most of the previous studies [ 105 , 106 , 107 ], but it should had been distinguished [ 64 , 80 , 84 , 88 ] into state anxiety, a temporary context-dependent condition, and trait anxiety, a more stable tendency to perceive and respond to environmental burden with persistent worry and fear [ 101 , 108 ]. The evolution of both anxiety and depression was influenced by disease-related biological mechanisms, and individual lifestyle and personality factors [ 109 ]. Recent studies suggested that personality traits played a meaningful role: higher levels of neuroticism were linked to greater vulnerability to developing depression and anxiety, whereas traits such as extraversion and openness may confer a degree of psychological resilience in individuals with MS [ 110 ].

State anxiety correlated with cerebrospinal fluid levels of interleukin-2, and increased severity of state anxiety and depressive symptoms correlated with MS activity. This association was present even in cases of subclinical inflammation on MRI, and psychiatric symptoms were reduced following the resolution of the inflammation [ 111 ]. In contrast, trait anxiety did not seem to be affected by inflammatory status, further supporting a specific relationship between neuroinflammation and transient affective disturbances in patients with MS. Emotional symptoms with sudden onset or worsening may be potential indicators of underlying disease activity, emphasizing the importance of careful evaluation in such contexts [ 101 ].

3.2.2. Imaging Findings

Structural MRI

Anxiety in PwMS showed no consistent relationship with lesion load, specific lesion distribution (infratentorial lesions) or regional atrophy on conventional MRI, unlike depression [ 58 , 60 , 61 , 64 , 66 ]. Anxiety was strongly related to depression, fatigue, and secondary progressive disease [ 61 , 112 ]. Studies that focused on limbic and brainstem structures did not yield robust and reproducible findings. While subtle alterations in limbic connectivity or cognitive performance were reported, these did not seem sufficient to delineate a clear neuroanatomical substrate. Even if a higher incidence of the lesion load in the locus coeruleus (noradrenergic system) in patients with anxiety than in those without was described, it did not reach statistical significance [ 59 ]. No correlations were found between lesion load in raphe nuclei (serotonergic system) and cerebellar or brainstem lesion topography [ 59 ]. Instead, anxiety in MS was likely influenced by a combination of psychological, cognitive, and contextual factors, including disease uncertainty and stress-related responses. Collectively, these findings supported a model in which depression in MS was more closely linked to structural and network-level brain damage, whereas anxiety appeared to reflect a more complex and less structurally determined interplay between neurobiological and psychosocial mechanisms [ 63 , 113 ].

Anxiety levels were associated with higher normalized brain volumes, in contrast to the typically reduced brain volumes in PwMS [ 59 ]. This was explained by the pathophysiology of anxiety, which is less driven by neurodegeneration and more influenced by psychological and behavioral factors than depression.

Generalized anxiety disorder was also studied in late-life patients, and it was correlated with reduced cortical thickness in orbito-frontal cortex, anterior cingulate cortex and inferior frontal regions, areas involved in emotional regulation and threat appraisal; however, after adjustments, only the left rostral anterior cingulate cortex was statistically significantly correlated. Additionally, the brain volumes in the right inferior frontal gyrus, pars triangularis and pars opercularis correlated moderately, and no association was seen between WM hyperintensity burden, WM integrity of diffusivity and anxiety [ 113 ]. In a retrospective study by Hillyer et al. [ 60 ], performed using 7T MRI, a significant relationship between the presence and volume of lesions in the limbic system and anxiety was observed.

PwMS with fatigue and severe anxiety exhibit increased caudate volume and reduced cortical thickness in the left parietal cortex compared to those without fatigue [ 66 ].

Diffusion tensor imaging

The correlation between anxiety and lesion topography in limbic white matter circuits, particularly the septo-fornical pathway, column, and body of the fornix [ 62 ], was evidenced using lesion mapping. That pointed to a substrate at the level of the limbic circuit that is distinct from global white matter lesion burden.

Anxiety was correlated with reduced structural connectivity, predominantly in the hippocampal and anterior insula regions, driven by fear overgeneralization [ 63 ]. FA was lower in the left cingulum and right uncinate fasciculus and negatively correlated with anxiety severity, whereas FA values were not correlated with anxiety in the general population [ 113 ], suggesting that anxiety in PwMS has an underlying WM tract pathophysiology.

Functional MRI

A combined longitudinal assessment of cortical atrophy on conventional MRI with normative rs-fMRI connectivity mapping to identify an anxiety-related prefrontal-limbic network suggested that anxiety symptoms were driven by network-level dysfunction rather than isolated structural damage [ 65 ]. Task-based fMRI highlighted functional alterations in fear-processing networks modulated by hippocampal-insular circuits, with an underlying mechanism based on generalized fear [ 63 ]. Complementary structural studies associated greater uncinate fasciculus (UF) lesion burden with more severe anxiety, independently of total lesion volume, whereas fornix injury was not significantly related to anxiety severity [ 58 , 62 , 114 ].

Figure 2 provides a schematic comparison of the main brain regions and neural pathways reported to be associated with depression and anxiety in patients with multiple sclerosis, highlighting both condition-specific and overlapping MRI correlates.

4. Discussion

The most consistent finding across the reviewed literature was that affective symptoms in MS were more closely related to the disruption of distributed neural circuits than to the total lesion burden [ 40 , 45 , 48 , 52 , 56 , 58 , 62 , 63 , 65 ]. This pattern was particularly evident in the cases of depression. Overall, structural MRI studies implicated the frontal, temporal, limbic, subcortical, and cerebellar regions associated with emotional regulation, reward processing, motivation, and cognitive control. The most common structural alterations reported were decreased cortical surface area or volume in the prefrontal, orbitofrontal, middle frontal, entorhinal, fusiform, and parahippocampal regions. Changes in the thalamus, globus pallidus, hippocampus and posterior cerebellum were also reported. These findings supported the view that depression in MS was a disorder linked to fronto-limbic and motivational networks, rather than a simple consequence of diffuse lesion accumulation [ 40 , 45 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 55 , 56 , 59 , 61 , 78 , 79 , 80 , 81 , 96 , 97 , 115 , 116 ]. This network pattern was particularly conspicuous in studies on RRMS and early MS. Studies confined to RRMS or early relapse-onset groups found abnormalities in dynamic functional connectivity, associative white matter tracts, cortical morphology, and limbic function. That suggested that circuit disruptions might cause symptoms before widespread neurodegeneration becomes the dominant pathology [ 100 , 101 , 102 , 103 , 104 ]. In early or relapse-onset cohorts, selective posterior cerebellar atrophy and frontotemporal cortical changes were often independent of the total lesion burden [ 47 , 55 ].

Diffusion MRI studies showed a fairly coherent disruption in the microstructure of WM tracts, particularly in the associative and limbic WM tracts [ 40 , 44 , 48 , 49 , 56 , 61 , 116 ]. Decreased fractional anisotropy and increased diffusivity were reported in the uncinate fasciculus, cingulum, fornix, and superior longitudinal fasciculus [ 44 , 48 , 49 ]. These WM tracts link the prefrontal cortex with the limbic and associative areas in accordance with abnormalities in mood regulation, reward processing, and executive control functions [ 48 , 49 , 56 , 91 , 92 , 93 , 116 ]. Lesions in defined depression-related pathways were associated with the presence or severity of depressive symptoms, but rather total lesion burden [ 40 , 48 , 56 , 116 ].

The functional MRI findings matched the network-based model. Altered connectivity was reported between the amygdala, hippocampus, prefrontal cortex, anterior cingulate cortex, and brainstem neuromodulatory systems [ 45 , 48 , 96 , 97 , 115 ]. There were also noted abnormalities in the default mode, salience, executive control, reward, serotonergic, noradrenergic, and cerebellar networks [ 42 , 45 , 52 , 94 , 95 , 96 , 97 ].

These studies enhanced the importance of fronto-limbic and fear-processing pathways in anxiety, although the evidence was not as comprehensive as for depression [ 58 , 60 , 62 , 63 , 65 ]. Abnormalities were reported in the UF, fornix, cingulum, amygdala, hippocampus, anterior insula, ACC, and DLPFC. The functional neuroimaging data indicated altered connectivity between the PFC and amygdala, as well as the hippocampus and PFC in threat appraisal and fear generalization networks [ 63 , 65 ]. Overall, the findings supported regional and connectivity abnormalities as potential MRI correlates of anxiety over global atrophy and total lesion burden.

The major point of contention was the link between affective symptoms and conventional MRI parameters. Depression was associated with various brain changes such as increased T2 lesion load, reduced overall brain volume, regional cortical atrophy, and lower WM volume [ 48 , 50 , 51 , 55 ]. In contrast, several studies reported no significant relationship between depression and global lesion load, total GM or WM volume, or conventional structural connectivity measures [ 41 , 46 , 47 , 56 ]. Those discrepancies indicated that global MRI measures may not be sensitive enough to detect focal abnormalities in mood-regulating networks. Although some studies linked thalamic atrophy to depression, others indicated that thalamic atrophy was more of a marker of broader MS-related neurodegeneration or cognitive impairment, rather than a depression-specific substrate [ 55 , 57 , 61 , 78 ]. Likewise, several studies showed hippocampal and amygdalar abnormalities, using methods assessing network topology and diffusion, while conventional volumetric studies failed to demonstrate mood-specific changes [ 41 , 46 , 48 , 56 , 61 ].

The cerebellar findings were inconsistent too. Depression was linked to selective posterior cerebellar atrophy, especially in affective cerebellar regions; however, other studies found no relationship between depressive symptoms and cerebellar lobular volume or infratentorial lesion load [ 47 , 59 ]. The brainstem findings followed a similar pattern. Lesions involving the raphe nuclei, locus coeruleus, medial midbrain, and pons were associated with depression [ 45 , 59 , 82 , 83 , 84 ]. The significance of some individual nuclei was not always statistically robust [ 59 ].

RRMS and early-MS studies identified focal cortical, tract-specific, or functional network abnormalities more often, while correlations with global brain atrophy and lesion burden, which emerged in mixed cohorts including patients with progressive disease, were less consistent [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 53 , 55 , 56 , 61 , 100 , 101 , 102 , 103 , 104 ]. In progressive MS, depression and MRI measures were strongly correlated with cumulative neurodegeneration and regional atrophy, as reduced olfactory bulb volume was associated with depression severity only in a subgroup of patients with progressive MS [ 53 ]. Likewise, longitudinal findings involving the thalamus, globus pallidus, and other subcortical reward-motivational centers suggested that later-stage depression was more related to degeneration of reward and motivational circuits, rather than to active inflammatory lesion formation [ 57 , 61 , 78 , 80 , 81 ].

The literature on anxiety was even less consistent. Several studies failed to identify an association between anxiety and lesion count, total lesion load, infratentorial lesions, regional gray- or white-matter volume, or T1 hypointense lesions [ 59 , 61 , 64 , 66 ]. Other studies reported significant associations with limbic lesions, fornix involvement, uncinate fasciculus lesion burden, cortical thinning in the dorsal prefrontal cortex, and reduced structural connectivity involving the hippocampus and anterior insula [ 58 , 60 , 62 , 63 ]. Volumetric findings were inconsistent as well. While some reports describe reduced cortical thickness or regional volume, others found higher normalized brain volume in patients with anxiety, suggesting that anxiety might not follow a simple neurodegenerative pattern [ 63 , 65 ]. The relationship between anxiety and progressive disease appeared to be predominantly clinical rather than radiological.

Anxiety was related to secondary progressive MS, fatigue, and depression, but conventional MRI lesion measures were not independently associated with these variables, [ 64 , 91 ]. Similarly, comparisons between the progressive MS and the relapsing–remitting MS cohorts demonstrated that anxiety burden may vary by phenotype, but those differences were heavily confounded by disability, fatigue and psychosocial factors [ 86 ]. Therefore, a higher prevalence or severity of anxiety in progressive MS cannot be used as evidence of a distinctive MRI pattern in progressive MS [ 64 , 86 , 91 ].

Another debated issue was the relationship between damage to the fornix and anxiety. Lesion mapping studies implicated the column and body of the fornix in anxiety, whereas other studies did not find a correlation between fornix injury and anxiety severity [ 58 , 62 ]. Similarly, a high-field 7 T study found limbic lesions associated with anxiety, whereas conventional field-strength studies generally did not find a consistent relationship between limbic lesion burden and anxiety [ 60 , 64 , 66 ].

The divergent findings could be attributed to several methodological factors. The first was the heterogeneity of the psychiatric assessment. Some studies assessed depression using instruments such as the BDI, BDI-II, HADS-D, HDRS, CES-D, CMDI, PHQ-2, and PHQ-9. Other studies used DSM-based diagnoses. These tools differ in their sensitivity, threshold for diagnosis, and contribution of somatic symptoms (e.g., fatigue, sleep disturbance and impaired concentration) to the total score [ 67 , 68 , 69 , 70 , 71 , 72 , 73 ]. Symptoms in MS might represent neurologic disease rather than depression and inflated associations in some cohorts [ 67 , 73 , 76 ].

Anxiety assessment was even more heterogeneous in nature. Some studies used HADS-A, others the STAI, or abbreviated state and trait inventories, and some did not distinguish between transient state anxiety and stable trait anxiety [ 58 , 60 , 62 , 63 , 64 , 65 , 66 , 80 , 88 ]. State anxiety was subject to change depending on inflammatory activity, relapse, diagnostic uncertainty, and recent diagnosis. In contrast, trait anxiety was more strongly driven by personality and long-term psychosocial vulnerability [ 45 , 80 , 84 , 88 ].

The second largest source of variability was associated with the type of imaging method used. The studies varied in field strengths (1.5 T to 7 T), spatial resolution, lesion detection sensitivity, sequence selection, and susceptibility to artifacts. Conventional T1- weighted and T2-weighted imaging, FLAIR, volumetric measurements, voxel-based morphometry, diffusion tensor imaging, high-angular-resolution diffusion imaging, tractography, resting-state functional MRI, task-based functional MRI, lesion-network mapping and free-water imaging each provided different information on aspects of disease pathology. A negative study on conventional MRI could be considered compatible with a positive result obtained either by diffusion or functional MRI, since these techniques assessed different biological processes.

The analytical strategies used varied widely among the studies. Some studies focused on global brain volume or overall lesion burden, while others focused on specific regions, tract-specific lesions, cortical thickness, connectivity networks, or even dynamic functional connectivity. ROI-based analysis techniques identified focal abnormalities that were diluted when measured using whole-brain techniques. Small sample sizes increased the risk of false-negative and unstable positive findings. Differences in correction for multiple comparisons, intracranial volume, age, disease duration, disability, treatment status, fatigue, cognition and vascular comorbidities further limited comparability.

The clinical heterogeneity was also significant. The included cohorts comprised RRMS, SPMS, progressive, early-MS, and mixed-phenotype populations with broad age, disease duration, disability, inflammatory activity, and extent of neurodegenerative damage. Most imaging data were obtained from cohorts of RRMS [ 42 , 43 , 44 , 55 , 61 ], early or relapse-onset MS [ 47 , 51 , 65 ], or mixed cohorts with predominantly relapse-onset disease. Progressive phenotypes were generally included within mixed cohorts or examined in subgroup analyses, as in the studies by Yaldizli et al. [ 53 ] and Nyári et al. [ 64 ] rather than being investigated in independent SPMS-only or PPMS-only imaging cohorts. Therefore, reported focal network abnormalities in younger RRMS populations were obscured in mixed or progressive cohorts by diffuse atrophy and accumulated structural damage [ 53 , 57 , 61 , 78 ].

Depression and anxiety often co-occurred, and both were linked to fatigue, cognitive impairment, pain, relapse activity, medication exposure, and psychosocial stress [ 45 , 64 , 68 , 80 , 85 , 86 , 87 , 88 , 89 , 91 , 98 , 99 ]. Many studies failed to account for these factors properly, which led to the confounding of general disease-related or behavioral effects with a particular psychiatric symptom [ 45 , 64 , 66 , 80 , 85 , 86 , 87 , 88 , 89 , 91 ]. In progressive MS, the accumulation, fatigue, decreased autonomy and chronic symptom burden had a greater impact on affective symptoms than on focal MRI abnormalities [ 64 , 86 , 91 ].

5. Limitations

This review had several limitations. The included studies had considerable heterogeneity in terms of imaging techniques, acquisition parameters, analytical approaches, study population, and adjustment for relevant clinical confounders, as well as a lack of a standardized reporting system. The incidence of RRMS and early MS was higher compared to progressive forms, limiting the generalizability of the results to SPMS and PPMS. Such methodological differences prevented the characterization of MRI-specific markers for depression or anxiety in MS.

6. Conclusions

Depression and anxiety are frequently reported in PwMS. Conventional structural MRI findings revealed a limited association with GM atrophy in patients with depression and partial independence from lesion load, while anxiety demonstrated weaker structural correlations. Advanced MRI studies provided stronger evidence of disrupted connectivity within the limbic, prefrontal and neuromodulation circuits. These findings enhance the knowledge about the neurobiological underpinnings of affective symptoms but do not currently support the use of MRI as an independent biomarker for depression or anxiety in MS. The relationship between MS and neuropsychological and neuropsychiatric symptoms remained unclear and multifactorial, including structural and functional brain abnormalities, inflammation, and psychosocial factors.

Future studies using larger cohorts with standardized protocols for conventional and advanced MRI may reveal the link between brain alterations and neuropsychiatric symptoms. Currently, MRI findings are considered only exploratory markers without validated clinical biomarkers for diagnosis, prognosis, or treatment selection.

Acknowledgments

During the preparation of this manuscript, the authors used ChatGPT Plus, Open AI 2026 for image generation to create a schematic comparative visual synthesis of the most commonly affected areas of the brain in PwMS and depression and/or anxiety. The authors have edited the output and take full responsibility for the content of this publication.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, L.S.P. and S.D.M.-C.; methodology, L.S.P., S.D.M.-C., M.L. and I.M.; investigation, L.S.P., S.D.M.-C., M.L. and A.I.; resources, L.S.P., A.V.B., I.M. and E.P.D.; data curation, L.S.P., S.D.M.-C. and M.L.; formal analysis, L.S.P., S.D.M.-C. and M.L.; validation, M.L., I.M. and E.P.D.; writing—original draft preparation, L.S.P. and S.D.M.-C.; writing—review and editing, L.S.P., S.D.M.-C., A.V.B., M.L., I.M. and E.P.D.; visualization, L.S.P. and M.L.; supervision, A.V.B., I.M. and E.P.D.; project administration, A.V.B. and L.S.P. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript: ACC Anterior Cingulate Cortex ADC Apparent Diffusion Coefficient AFDtot Apparent Fiber Density Total AUDIT Alcohol Use Disorders Identification Test BDI Beck Depression Inventory BDI-II Beck Depression Inventory-II BOLD Blood Oxygen Level-Dependent CES-D Center for Epidemiologic Studies Depression Scale CMDI Chicago Multiscale Depression Inventory CSF Cerebrospinal Fluid DIR Double Inversion Recovery DMN Default Mode Network DSM-V Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DTI Diffusion Tensor Imaging DWI Diffusion-Weighted Imaging ECN Executive Control Network EDSS Expanded Disability Status Scale EPI Echo Planar Imaging FA Fractional Anisotropy FC Functional Connectivity FLAIR Fluid-Attenuated Inversion Recovery fMRI Functional Magnetic Resonance Imaging FSS Fatigue Severity Scale FWF Free Water Fraction Gad+ Gadolinium-Enhancing GGT Gamma-Glutamyl Transferase GM Gray Matter GRE Gradient Recalled Echo HADS Hospital Anxiety and Depression Scale HADS-A Hospital Anxiety and Depression Scale—Anxiety HADS-D Hospital Anxiety and Depression Scale—Depression HARDI High Angular Resolution Diffusion Imaging HDRS Hamilton Depression Rating Scale HPA Hypothalamic–Pituitary–Adrenal HRQoL Health-Related Quality of Life MADRS Montgomery–Åsberg Depression Rating Scale MD Mean Diffusivity MMSE Mini-Mental State Examination MP-RAGE Magnetization Prepared Rapid Gradient Echo MPR2RAGE Magnetization Prepared 2 Rapid Gradient Echoes MPRAGE Magnetization Prepared Rapid Acquisition Gradient Echo MRI Magnetic Resonance Imaging MS Multiple Sclerosis N/A Not Applicable NAWM Normal-Appearing White Matter NHPT Nine-Hole Peg Test NuFO Number of Fiber Orientations OFC Orbitofrontal Cortex PCC Posterior Cingulate Cortex PD Proton Density PFC Prefrontal Cortex PHQ-2 Patient Health Questionnaire-2 PHQ-9 Patient Health Questionnaire-9 PROMIS Patient-Reported Outcomes Measurement Information System PwMS People with Multiple Sclerosis RD Radial Diffusivity ROI Region of Interest RRMS Relapsing–Remitting Multiple Sclerosis rs-fMRI Resting-State Functional Magnetic Resonance Imaging S-ANX State Anxiety SN Salience Network SPMS Secondary Progressive Multiple Sclerosis STAI State-Trait Anxiety Inventory STAI-T State-Trait Anxiety Inventory—Trait STAIS-5 State Anxiety Inventory Short Form STAIT-5 Trait Anxiety Inventory Short Form SVR Support Vector Regression T-ANX Trait Anxiety T1W T1-Weighted T2LL T2 Lesion Load T2W T2-Weighted UF Uncinate Fasciculus VBM Voxel-Based Morphometry WM White Matter WML White Matter Lesion WMLL White Matter Lesion Load

Appendix A. Research Framework

Appendix A.1. Research Question and Objectives

The objective of this review was to highlight the link between structural, microstructural and functional brain MRI markers and depression and/or anxiety in patients with MS. The review question was structured according to the PICOS framework ( Figure A1 ). We focused on patients with confirmed MS, independent of disease phenotype or treatment status (Population), who received structured clinical interviews, were assessed using validated psychometric tools, or had established diagnostic criteria. They were linked to measures derived from MRI (Intervention/Exposure). Healthy controls, patients without depression and/or anxiety, lower symptom severity, or within-cohort comparisons based on affective symptom scores were used as comparators. The outcomes of interest were the associations between depression or anxiety and MRI markers including lesion load and topography, cortical thickness, cortical surface area, regional and global brain volumes, gray- and white-matter abnormalities, diffusion metrics, tract integrity, functional activation, and structural or functional connectivity (Outcomes). The eligibility criteria were original adult human observational or interventional studies. The exclusion criteria were non-English articles, reviews, abstracts, editorials, conference papers, letters, errata, case reports, pediatric or non-human studies, studies without MRI-psychiatric correlation analyses, and studies in which patients with MS were only a small subgroup of a heterogeneous cohort (Study design).

Appendix A.2. Search Strategy

The database-specific search strategies were structured according to the PICOS framework. The detailed search terms, filters, date restrictions, and number of records obtained for each database are summarized in Figure A2 , Figure A3 and Figure A4 .

References

1. Eiman M.A.M. Elucidating the Molecular Basis of Multiple Sclerosis and Understanding the Disease Pathophysiology Immunome Res. 2016 12 3 10.4172/1745-7580.10000125

2. Mohammed E.M.A. Multiple sclerosis is prominent in the Gulf states: Review Pathogenesis 2016 3 19 38 10.1016/j.pathog.2016.04.001

3. Bjornevik K. Cortese M. Healy B.C. Kuhle J. Mina M.J. Leng Y. Elledge S.J. Niebuhr D.W. Scher A.I. Munger K.L. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis Science 2022 375 296 301 10.1126/science.abj8222 35025605

4. Weidauer S. Raab P. Hattingen E. Diagnostic approach in multiple sclerosis with MRI: An update Clin. Imaging 2021 78 276 285 10.1016/j.clinimag.2021.05.025 34174655

5. Sarbu N. Shih R.Y. Jones R.V. Horkayne-Szakaly I. Oleaga L. Smirniotopoulos J.G. White matter diseases with radiologic-pathologic correlation Radiographics 2016 36 1426 1447 10.1148/rg.2016160031 27618323

6. Hemond C.C. Bakshi R. Magnetic Resonance Imaging in Multiple Sclerosis Cold Spring Harb. Perspect. Med. 2018 8 a028969 10.1101/cshperspect.a028969 29358319 PMC5932576

7. Bruschi N. Boffa G. Inglese M. Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: From pathology to clinical practice Eur. Radiol. Exp. 2020 4 59 10.1186/s41747-020-00186-x 33089380 PMC7578213

8. Filippi M. Evangelou N. Kangarlu A. Inglese M. Mainero C. Horsfield M.A. Rocca M.A. Ultra-high-field MR imaging in multiple sclerosis J. Neurol. Neurosurg. Psychiatry 2014 85 60 66 10.1136/jnnp-2013-305246 23813636

9. Solomon A.J. Pettigrew R. Naismith R.T. Chahin S. Krieger S. Weinshenker B. Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria Mult. Scler. J. 2021 27 250 258 10.1177/1352458520910496 32162581

10. Montalban X. Lebrun-Frénay C. Oh J. Arrambide G. Moccia M. Amato M.P. Amezcua L. Banwell B. Bar-Or A. Barkhof F. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria Lancet Neurol. 2025 24 850 865 10.1016/S1474-4422(25)00270-4 40975101

11. Brisset J.C. Vukusic S. Cotton F. Update on brain MRI for the diagnosis and follow-up of MS patients Presse Med. 2021 50 104067 10.1016/j.lpm.2021.104067 33989722

12. Geraldes R. Juryńczyk M. dos Passos G. Prichler A. Chung K. Hagens M. Ruggieri S. Huerga E. Sastre-Garriga J. Enzinger C. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis J. Neurol. Neurosurg. Psychiatry 2020 9 388 391 10.1136/jnnp-2019-322369 32034114

13. Harada M. Cutting-edge of advanced MRI for demyelinating diseases Rinsho Shinkeigaku 2013 53 1094 1096 10.5692/clinicalneurol.53.1094 24291889

14. Benedict R.H.B. Amato M.P. DeLuca J. Geurts J.J.G. Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues Lancet Neurol. 2020 19 860 871 10.1016/S1474-4422(20)30277-5 32949546 PMC10011205

15. Margoni M. Preziosa P. Rocca M.A. Filippi M. Depressive symptoms, anxiety and cognitive impairment: Emerging evidence in multiple sclerosis Transl. Psychiatry 2023 13 264 10.1038/s41398-023-02555-7 37468462 PMC10356956

16. McGuigan C. Hutchinson M. Unrecognised symptoms of depression in a community–based population with multiple sclerosis J. Neurol. 2006 253 219 223 10.1007/s00415-005-0963-0 16177840

17. Korostil M. Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients Mult. Scler. J. 2007 13 67 72 10.1177/1352458506071161 17294613

18. Turner A.P. Alschuler K.N. Hughes A.J. Beier M. Haselkorn J.K. Sloan A.P. Ehde D.M. Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder Curr. Neurol. Neurosci. Rep. 2016 16 106 10.1007/s11910-016-0706-x 27848174

19. Marrie R.A. Walld R. Bolton J.M. Sareen J. Walker J.R. Patten S.B. Singer A. Lix L.M. Hitchon C.A. El-Gabalawy R. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data BMC Res. Notes 2017 10 619 10.1186/s13104-017-2958-1 29178935 PMC5702192

20. Mitincu-Caramfil S.-D. Stoian A.P. Moroianu L.-A. Plesea-Condratovici C. Bradeanu A.V. Drima E. Does the Interaction Between Alcohol Use and Depression Exacerbate Hyperglycemia Risk? A Cross-Sectional Study Beyond Additive Effects Medicina 2025 61 1380 10.3390/medicina61081380 40870425 PMC12387687

21. Bradeanu A. Tudor R. Sirbu P.D. Ciubara A. Pascu L. Ciubara A.B. Alcohol Consumption-Implications in Orthopedic Trauma Am. J. Psychiatry Neurosci. 2017 5 24 10.11648/j.ajpn.s.2017050601.34

22. Bradeanu A. Pascu L. Ungurianu S. Tutunaru D. Rebegea L. Terpan M. Ciubara A. The Effect of Behaviour in Patients Who Are Hospitalized and Suffer from Alcohol Withdrawal BRAIN Broad Res. Artif. Intell. Neurosci. 2019 10 46 51 10.70594/brain/v10.s2/5

23. Mitincu-Caramfil S.D. Plesea-Condratovici A. Balta A.A.S. Bulza V. Bradeanu A.V. Moroianu L.A. Isailă O.M. Drima E. The Impact of Chronic Alcohol Consumption on Cognitive Function in Older People J. Clin. Med. 2025 14 4595 10.3390/JCM14134595 40648970 PMC12249728

24. Moroianu M. Moroianu L.A. Isailă O.-M. PleșEa-Condratovici C. Mitincu-Caramfil S.D. Matei M.N. Psychological and Social Trajectories During Dental Treatment: A Prospective Cohort Study on Oral Health-Related Quality of Life Dent. J. 2026 14 223 10.3390/dj14040223 42041676 PMC13114271

25. Bradeanu A.V. Bounegru I. Pascu L.S. Ciubara A. The Impact of Dementia on Patients with Hip Fracture Discoveries 2024 12 e188 10.15190/d.2024.7 39323738 PMC11421493

26. Peres D.S. Viero F.T. Rodrigues P. Bernardes L.d.B. da Silva N.A.R. Lima I.R. Martins G. Silveira P.C.L. Ferreira M.d.A. Silva A.M. Characterization of Depression- and Anxiety-Like Behaviours in a Mouse Model of Relapsing-Remitting Multiple Sclerosis J. Neuroimmune Pharmacol. 2023 18 235 247 10.1007/s11481-023-10080-z 37526817

27. Maresova P. Krejcar O. Maskuriy R. Abu Bakar N.A. Selamat A. Truhlarova Z. Horak J. Joukl M. Vítkova L. Challenges and opportunity in mobility among older adults–key determinant identification BMC Geriatr. 2023 23 447 10.1186/s12877-023-04106-7 37474928 PMC10360303

28. Albanese A.M. Bartz-Overman C. Parikh T. Thielke S.M. Associations Between Activities of Daily Living Independence and Mental Health Status Among Medicare Managed Care Patients J. Am. Geriatr. Soc. 2020 68 1301 1306 10.1111/jgs.16423 32196634

29. Chertcoff A.S. Yusuf F.L. Zhu F. Evans C. Fisk J.D. Zhao Y. Marrie R.A. Tremlett H. Psychiatric Comorbidity During the Prodromal Period in Patients with Multiple Sclerosis Neurology 2023 101 E2026 E2034 10.1212/WNL.0000000000207843 37748884 PMC10662981

30. Silveira C. Guedes R. Maia D. Curral R. Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art Psychiatry Investig. 2019 16 877 888 10.30773/pi.2019.0106 31805761 PMC6933139

31. Solomon A.J. Ascherio A. Early Diagnosis of Multiple Sclerosis Neurology 2021 96 1111 1112 10.1212/WNL.0000000000012087 33903189

32. Raimo S. Santangelo G. Trojano L. The emotional disorders associated with multiple sclerosis Handbook of Clinical Neurology 1st ed. Heilman K. Nadeau S. Elsevier Amsterdam, The Netherlands 2021 197 220 10.1016/B978-0-12-822290-4.00009-8 34389118

33. Makhani N. Tremlett H. The multiple sclerosis prodrome Nat. Rev. Neurol. 2021 17 515 521 10.1038/s41582-021-00519-3 34155379 PMC8324569

34. Bjornevik K. Munger K.L. Cortese M. Barro C. Healy B.C. Niebuhr D.W. Scher A.I. Kuhle J. Ascherio A. Serum Neurofilament Light Chain Levels in Patients with Presymptomatic Multiple Sclerosis JAMA Neurol. 2020 77 58 10.1001/jamaneurol.2019.3238 31515562 PMC6745051

35. Yusuf F.L.A. Ng B.C. Wijnands J.M.A. Kingwell E. Marrie R.A. Tremlett H. A systematic review of morbidities suggestive of the multiple sclerosis prodrome Expert Rev. Neurother. 2020 20 799 819 10.1080/14737175.2020.1746645 32202173

36. Marrie R.A. Allegretta M. Barcellos L.F. Bebo B. Calabresi P.A. Correale J. Davis B. De Jager P.L. Gasperi C. Greenbaum C. From the prodromal stage of multiple sclerosis to disease prevention Nat. Rev. Neurol. 2022 18 559 572 10.1038/s41582-022-00686-x 35840705

37. Wijnands J.M. Zhu F. Kingwell E. Zhao Y. Ekuma O. Lu X. Evans C. Fisk J.D. Marrie R.A. Tremlett H. Five years before multiple sclerosis onset: Phenotyping the prodrome Mult. Scler. J. 2019 25 1092 1101 10.1177/1352458518783662 29979093

38. Filippi M. Brück W. Chard D. Fazekas F. Geurts J.J.G. Enzinger C. Hametner S. Kuhlmann T. Preziosa P. Rovira À. Association between pathological and MRI findings in multiple sclerosis Lancet Neurol. 2019 18 198 210 10.1016/S1474-4422(18)30451-4 30663609

39. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 2021 372 n71 10.1136/bmj.n71 33782057 PMC8005924

40. Baller E.B. Sweeney E.M. Cieslak M. Robert-Fitzgerald T. Covitz S.C. Martin M.L. Schindler M.K. Bar-Or A. Elahi A. Larsen B.S. Mapping the Relationship of White Matter Lesions to Depression in Multiple Sclerosis Biol. Psychiatry 2024 95 1072 1080 10.1016/j.biopsych.2023.11.010 37981178 PMC11101593

41. Kever A. Buyukturkoglu K. Levin S.N. Riley C.S. De Jager P. Leavitt V.M. Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation Mult. Scler. J. 2022 28 228 236 10.1177/13524585211018349 34037495

42. Romanello A. Krohn S. von Schwanenflug N. Chien C. Bellmann-Strobl J. Ruprecht K. Paul F. Finke C. Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis Neuroimage Clin. 2022 36 103203 10.1016/j.nicl.2022.103203 36179389 PMC9668632

43. Kopchak O.O. Odintsova T.A. Cognitive impairment and depression in patients with relapsing–remitting multiple sclerosis depending on age and neuroimaging findings Egypt. J. Neurol. Psychiatry Neurosurg. 2021 57 119 10.1186/s41983-021-00376-3 34511865 PMC8424158

44. Beaudoin A.-M. Rheault F. Theaud G. Laberge F. Whittingstall K. Lamontagne A. Descoteaux M. Modern Technology in Multi-Shell Diffusion MRI Reveals Diffuse White Matter Changes in Young Adults with Relapsing-Remitting Multiple Sclerosis Front. Neurosci. 2021 15 665017 10.3389/fnins.2021.665017 34447292 PMC8383891

45. Carotenuto A. Wilson H. Giordano B. Caminiti S.P. Chappell Z. Williams S.C.R. Hammers A. Silber E. Brex P. Politis M. Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications J. Neurol. 2020 267 2042 2053 10.1007/s00415-020-09806-3 32219555 PMC7320961

46. Golde S. Heine J. Pöttgen J. Mantwill M. Lau S. Wingenfeld K. Otte C. Penner I.-K. Engel A.K. Heesen C. Distinct Functional Connectivity Signatures of Impaired Social Cognition in Multiple Sclerosis Front. Neurol. 2020 11 507 10.3389/fneur.2020.00507 32670178 PMC7330009

47. Lazzarotto A. Margoni M. Franciotta S. Zywicki S. Riccardi A. Poggiali D. Anglani M. Gallo P. Selective Cerebellar Atrophy Associates with Depression and Fatigue in the Early Phases of Relapse-Onset Multiple Sclerosis Cerebellum 2020 19 192 200 10.1007/s12311-019-01096-4 31898280

48. van Geest Q. Boeschoten R.E. Keijzer M.J. Steenwijk M.D. Pouwels P.J. Twisk J.W. Smit J.H. Uitdehaag B.M. Geurts J.J. van Oppen P. Fronto-limbic disconnection in patients with multiple sclerosis and depression Mult. Scler. J. 2019 25 715 726 10.1177/1352458518767051 29587565 PMC6439942

49. Hassan T.A. Elkholy S.F. Mahmoud B.E. ElSherbiny M. Multiple sclerosis and depressive manifestations: Can diffusion tensor MR imaging help in the detection of microstructural white matter changes? Egypt. J. Radiol. Nucl. Med. 2019 50 31 10.1186/s43055-019-0033-8

50. Pravatà E. Rocca M.A. Valsasina P. Riccitelli G.C. Gobbi C. Comi G. Falini A. Filippi M. Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis Mult. Scler. J. 2017 23 1864 1874 10.1177/1352458517692886 28169581

51. Rojas J.I. Sanchez F. Patrucco L. Miguez J. Besada C. Cristiano E. Brain structural changes in patients in the early stages of multiple sclerosis with depression Neurol. Res. 2017 39 596 600 10.1080/01616412.2017.1298279 28245725

52. Bonavita S. Sacco R. Esposito S. D’AMbrosio A. Della Corte M. Corbo D. Docimo R. Gallo A. Lavorgna L. Cirillo M. Default mode network changes in multiple sclerosis: A link between depression and cognitive impairment? Eur. J. Neurol. 2017 24 27 36 10.1111/ene.13112 27633185

53. Yaldizli Ö. Penner I. Yonekawa T. Naegelin Y. Kuhle J. Pardini M. Chard D.T. Stippich C. Kira J. Bendfeldt K. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis Eur. J. Neurol. 2016 23 510 519 10.1111/ene.12891 26699999

54. Kallaur A.P. Lopes J. Oliveira S.R. Simão A.N.C. Reiche E.M.V. de Almeida E.R.D. Morimoto H.K. de Pereira W.L.C.J. Alfieri D.F. Borelli S.D. Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation Mol. Neurobiol. 2016 53 5191 5202 10.1007/s12035-015-9443-4 26399644

55. Nygaard G.O. Walhovd K.B. Sowa P. Chepkoech J.-L. Bjørnerud A. Due-Tønnessen P. Landrø N.I. Damangir S. Spulber G. Storsve A.B. Cortical thickness and surface area relate to specific symptoms in early relapsing–remitting multiple sclerosis Mult. Scler. J. 2015 21 402 414 10.1177/1352458514543811 25139946

56. Nigro S. Passamonti L. Riccelli R. Toschi N. Rocca F. Valentino P. Nisticò R. Fera F. Quattrone A. Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression Mult. Scler. J. 2015 21 1003 1012 10.1177/1352458514558474 25533294

57. Štecková T. Hluštík P. Sládková V. Odstrčil F. Mareš J. Kaňovský P. Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis J. Neurol. Sci. 2014 342 62 68 10.1016/j.jns.2014.04.026 24819917

58. Baller E.B. Luo A.C. Schindler M.K. Cooper E.C. Pecsok M.K. Cieslak M.C. Martin M.L. Bar-Or A. Elahi A. Perrone C.M. Uncinate Fasciculus Lesion Burden and Anxiety in Multiple Sclerosis JAMA Netw. Open 2025 8 e254751 10.1001/jamanetworkopen.2025.4751 40227683 PMC11997724

59. Giofrè F. Lugaresi A. Baccari F. Lui E. Roberts S. Malpas C. Kalincik T. The topography of infratentorial lesions in depression and anxiety in multiple sclerosis J. Neurol. 2025 272 420 10.1007/s00415-025-13167-0 40418350 PMC12106590

60. Hillyer A. Sharma M. Kuurstra A. Rosehart H. Menon R. Morrow S.A. Association between limbic system lesions and anxiety in persons with multiple sclerosis Mult. Scler. Relat. Disord. 2023 79 105021 10.1016/j.msard.2023.105021 37801955

61. Riemer F. Skorve E. Pasternak O. Zaccagna F. Lundervold A.J. Torkildsen Ø. Myhr K.-M. Grüner R. Microstructural changes precede depression in patients with relapsing-remitting Multiple Sclerosis Commun. Med. 2023 3 90 10.1038/s43856-023-00319-4 37349545 PMC10287644

62. Palotai M. Mike A. Cavallari M. Strammer E. Orsi G. Healy B.C. Schregel K. Illes Z. Guttmann C.R. Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis Mult. Scler. J. 2018 24 1105 1114 10.1177/1352458517711273 28548605

63. Meyer-Arndt L. Rust R. Bellmann-Strobl J. Schmitz-Hübsch T. Marko L. Forslund S. Scheel M. Gold S.M. Hetzer S. Paul F. Neurobehavioral mechanisms of fear and anxiety in multiple sclerosis Commun. Med. 2025 5 345 10.1038/s43856-025-01085-1 40783619 PMC12335550

64. Nyári A. Kokas Z. Szamosi S. Fricska-Nagy Z. Kincses Z.T. Füvesi J. Biernacki T. Klivényi P. Bencsik K. Sandi D. Fatigue and depression influence the prevalence of anxiety in patients with multiple sclerosis Neurol. Sci. 2025 46 325 334 10.1007/s10072-024-07737-9 39174771

65. Ellwardt E. Muthuraman M. Gonzalez-Escamilla G. Chirumamilla V.C. Luessi F. Bittner S. Zipp F. Groppa S. Fleischer V. Network alterations underlying anxiety symptoms in early multiple sclerosis J. Neuroinflamm. 2022 19 119 10.1186/s12974-022-02476-0 35610651 PMC9131528

66. Chalah M.A. Kauv P. Créange A. Hodel J. Lefaucheur J.-P. Ayache S.S. Neurophysiological, radiological and neuropsychological evaluation of fatigue in multiple sclerosis Mult. Scler. Relat. Disord. 2019 28 145 152 10.1016/j.msard.2018.12.029 30594815

67. Feinstein A. Multiple sclerosis and depression Mult. Scler. J. 2011 17 1276 1281 10.1177/1352458511417835 22058085

68. Wood B. Van Der Mei I.A.F. Ponsonby A.-L. Pittas F. Quinn S. Dwyer T. Lucas R.M. Taylor B. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis Mult. Scler. J. 2013 19 217 224 10.1177/1352458512450351 22729988

69. Mustac F. Pasic H. Medic F. Bjedov B. Vujevic L. Alfirevic M. Vidrih B. Tudor K.I. Pasic M.B. Anxiety and depressioon as comorbidities of Multiple Sclerosis Psychiatr. Danub. 2021 33 480 485 34718269

70. Alarcia R. Ara J.R. Bertol V. Predicting factors for depression in multiple sclerosis Neurologia 2004 19 364 368 15273883

71. Palladino R. Chataway J. Majeed A. Marrie R.A. Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality Neurology 2021 97 e1322 e1333 10.1212/WNL.0000000000012610 34470802 PMC8480403

72. Salmen A. Hoepner R. Fleischer V. Heldt M. Gisevius B. Motte J. Ruprecht K. Schneider R. Fisse A.L. Grüter T. Factors associated with depressive mood at the onset of multiple sclerosis-an analysis of 781 patients of the German NationMS cohort Ther. Adv. Neurol. Disord. 2023 16 17562864231197309 10.1177/17562864231197309 37692259 PMC10492471

73. Brasanac J. Heine J. Chien C. A Review of Sex Differences in Neurodegeneration and Psychological Comorbidities in Multiple Sclerosis and Related Disorders Neurodegener. Dis. 2025 25 21 35 10.1159/000544813 39970892

74. Dinu Iacob A. Confederat L.-G. Dragostin I. Morariu I.D. Tutunaru D. Dragostin O.M. Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress Curr. Issues Mol. Biol. 2025 47 709 10.3390/cimb47090709 41020831 PMC12468458

75. Tătaru I. Gardikiotis I. Dragostin O.-M. Confederat L. Gîrd C. Zamfir A.-S. Morariu I.D. Chiţescu C.L. Iacob A.D. Popescu L.C. Multilevel Assessment of Glycemic, Hormonal, and Oxidative Parameters in an Experimental Diabetic Female Rat Model Biomedicines 2025 13 922 10.3390/biomedicines13040922 40299518 PMC12024543

76. Marrie R.A. Patten S.B. Berrigan L.I. Tremlett H. Wolfson C. Warren S. Leung S. Fiest K.M. McKay K.A. Fisk J.D. Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis Int. J. MS Care 2018 20 76 84 10.7224/1537-2073.2016-110 29670493 PMC5898919

77. Marrie R. Horwitz R. Cutter G. Tyry T. Campagnolo D. Vollmer T. The burden of mental comorbidity in multiple sclerosis: Frequent, underdiagnosed, and undertreated Mult. Scler. J. 2009 15 385 392 10.1177/1352458508099477 19153176

78. Stuke H. Hanken K. Hirsch J. Klein J. Wittig F. Kastrup A. Hildebrandt H. Cross-Sectional and Longitudinal Relationships between Depressive Symptoms and Brain Atrophy in MS Patients Front. Hum. Neurosci. 2016 10 622 10.3389/fnhum.2016.00622 28018194 PMC5159697

79. Gobbi C. Rocca M. Riccitelli G. Pagani E. Messina R. Preziosa P. Colombo B. Rodegher M. Falini A. Comi G. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis Mult. Scler. J. 2014 20 192 201 10.1177/1352458513493684 23812284

80. Nieuwenhuys R. Voogd J. Huijzen C. The Human Central Nervous System 4th ed. Springer Science & Business Media Springer New York, NY, USA 2008 967p

81. Hong S. Hikosaka O. The Globus Pallidus Sends Reward-Related Signals to the Lateral Habenula Neuron 2008 60 720 729 10.1016/j.neuron.2008.09.035 19038227 PMC2638585

82. Baalbaki M. Depression Symptoms Moderate Link Between Infratentorial and Cervical Cord T2 Lesions on Gait Speed in Relapsing-Remitting Multiple Sclerosis [Internet] Master’s Thesis Icahn School of Medicine at Mount Sinai New York, NY, USA 2025 Available online: https://www.proquest.com/openview/d990715328b0f2e9d3cdcea8570a46dc/1?pq-origsite=gscholar&cbl=18750&diss=y (accessed on 25 April 2026)

83. Fibiger H.C. The Neurobiological Substrates of Depression in Parkinson’s Disease: A Hypothesis Can. J. Neurol. Sci./J. Can. Des Sci. Neurol. 1984 11 105 107 10.1017/S0317167100046230 6324981

84. Paulus W. Jellinger K. The Neuropathologic Basis of Different Clinical Subgroups of Parkinson’s Disease J. Neuropathol. Exp. Neurol. 1991 50 743 755 10.1097/00005072-199111000-00006 1748881

85. Berg D. Supprian T. Thomae J. Warmuth-Metz M. Horowski A. Zeiler B. Magnus T. Rieckman P. Becker G. Lesion pattern in patients with multiple sclerosis and depression Mult. Scler. J. 2000 6 156 162 10.1191/135245800701566016 10871826

86. Taylor W.D. Aizenstein H.J. Alexopoulos G.S. The vascular depression hypothesis: Mechanisms linking vascular disease with depression Mol. Psychiatry 2013 18 963 974 10.1038/mp.2013.20 23439482 PMC3674224

87. Razek A.A.K.A. El-Serougy L. Abdelsalam M. Gaballa G. Talaat M. Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics Neuroradiology 2018 60 169 177 10.1007/s00234-017-1955-3 29218370

88. Filippi M. Pagani E. Preziosa P. Rocca M.A. The Role of DTI in Multiple Sclerosis and Other Demyelinating Conditions Diffusion Tensor Imaging Springer New York, NY, USA 2016 331 341 10.1007/978-1-4939-3118-7_16

89. Feinstein A. O’COnnor P. Akbar N. Moradzadeh L. Scott C. Lobaugh N. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients Mult. Scler. J. 2010 16 189 196 10.1177/1352458509355461 20007425

90. Masuccio F.G. Gamberini G. Calabrese M. Solaro C. Imaging and Depression in Multiple Sclerosis: A Historical Perspective Neurol. Sci. 2021 42 835 845 10.1007/s10072-020-04951-z 33411192

91. Jaeger S. Paul F. Scheel M. Brandt A. Heine J. Pach D. Witt C.M. Bellmann-Strobl J. Finke C. Multiple sclerosis–related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex Mult. Scler. J. 2019 25 554 564 10.1177/1352458518758911 29464981

92. Fuchs T.A. Dwyer M.G. Kuceyeski A. Choudhery S. Carolus K. Li X. Mallory M. Weinstock-Guttman B. Jakimovski D. Ramasamy D. White matter tract network disruption explains reduced conscientiousness in multiple sclerosis Hum. Brain Mapp. 2018 39 3682 3690 10.1002/hbm.24203 29740964 PMC6866584

93. Hayden B.Y. Platt M.L. Neurons in Anterior Cingulate Cortex Multiplex Information about Reward and Action J. Neurosci. 2010 30 3339 3346 10.1523/JNEUROSCI.4874-09.2010 20203193 PMC2847481

94. Pucak M.L. Carroll K.A.L. Kerr D.A. Kaplin A.L. Kerr D.A. Ai K. Neuropsychiatric manifestations of depression in multiple sclerosis: Neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression Dialogues Clin. Neurosci. 2007 9 125 139 10.31887/DCNS.2007.9.2/mpucak 17726912 PMC3181849

95. Heitmann H. Andlauer T.F.M. Korn T. Mühlau M. Henningsen P. Hemmer B. Ploner M. Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms Mult. Scler. J. 2022 28 1020 1027 10.1177/1352458520972279 33179588 PMC9131410

96. Lombardi G. Leveraro E. Cipriano E. Sirito T. Cellerino M. Nasone L. Serafini G. Ghio L. Escelsior A. Inglese M. Functional and effective connectivity disruptions of the dopaminergic reward circuit in multiple sclerosis patients with depression J. Neurol. Neurosurg. Psychiatry 2026 97 692 698 10.1136/jnnp-2025-336798 41825870 PMC13479270

97. Rocca M.A. Pravatà E. Valsasina P. Radaelli M. Colombo B. Vacchi L. Gobbi C. Comi G. Falini A. Filippi M. Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression Hum. Brain Mapp. 2015 36 5051 5063 10.1002/hbm.22992 26366641 PMC6869286

98. Beiske A.G. Svensson E. Sandanger I. Czujko B. Pedersen E.D. Aarseth J.H. Myhr K.M. Depression and anxiety amongst multiple sclerosis patients Eur. J. Neurol. 2008 15 239 245 10.1111/j.1468-1331.2007.02041.x 18215155

99. Fahy A. Maguire R. Anxiety in people with multiple sclerosis during the COVID-19 pandemic: A mixed-methods survey Rehabil. Psychol. 2024 69 118 128 10.1037/rep0000528 37956089

100. Jellinger K.A. Depression and anxiety in multiple sclerosis. Review of a fatal combination J. Neural Transm. 2024 131 847 869 10.1007/s00702-024-02792-0 38869643

101. Menculini G. Gentili L. Gaetani L. Mancini A. Sperandei S. Di Sabatino E. Chipi E. Salvadori N. Tortorella A. Parnetti L. Clinical correlates of state and trait anxiety in multiple sclerosis Mult. Scler. Relat. Disord. 2023 69 104431 10.1016/j.msard.2022.104431 36470171

102. Hoang H. Laursen B. Stenager E.N. Stenager E. Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis Mult. Scler. J. 2016 22 347 353 10.1177/1352458515588973 26041803

103. Burns M.N. Nawacki E.B. Siddique J.D. Pelletier D. Mohr D.C. Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients with Multiple Sclerosis Psychosom. Med. 2013 75 76 82 10.1097/PSY.0b013e3182757b2b 23197840 PMC3538885

104. López M.L.B. Pérez E.R.P. Fernández E.G. Arnés M.d.R.M. Vázquez M.F. Hernández M.I.N. García E.G. Psychological Burden in Relapsing-Remitting Multiple Sclerosis: Sociodemographic and Clinical Determinants of Persistent Anxiety and Depression over a Six-Month Follow-Up Nurs. Rep. 2026 16 39 10.3390/nursrep16020039 41745864 PMC12942824

105. Pham T. Jetté N. Bulloch A.G. Burton J.M. Wiebe S. Patten S.B. The prevalence of anxiety and associated factors in persons with multiple sclerosis Mult. Scler. Relat. Disord. 2018 19 35 39 10.1016/j.msard.2017.11.003 29125968

106. Knowles L.M. Tingey J.L. Newman A.K. von Geldern G. Alschuler K.N. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis Mult. Scler. Relat. Disord. 2022 63 103918 10.1016/j.msard.2022.103918 35700673

107. Théaudin M. Romero K. Feinstein A. In multiple sclerosis anxiety, not depression, is related to gender Mult. Scler. J. 2016 22 239 244 10.1177/1352458515588582 26041798

108. Santangelo G. Sacco R. Siciliano M. Bisecco A. Muzzo G. Docimo R. De Stefano M. Bonavita S. Lavorgna L. Tedeschi G. Anxiety in Multiple Sclerosis: Psychometric properties of the State-Trait Anxiety Inventory Acta Neurol. Scand. 2016 134 458 466 10.1111/ane.12564 27219913

109. Saviola F. Pappaianni E. Monti A. Grecucci A. Jovicich J. De Pisapia N. Trait and state anxiety are mapped differently in the human brain Sci. Rep. 2020 10 11112 10.1038/s41598-020-68008-z 32632158 PMC7338355

110. Vaheb S. Mokary Y. Panah M.Y. Shaygannejad A. Afshari-Safavi A. Ghasemi M. Shaygannejad V. Ghaffary E.M. Mirmosayyeb O. Multiple sclerosis and personality traits: Associations with depression and anxiety Eur. J. Med. Res. 2024 29 171 10.1186/s40001-024-01772-0 38475891 PMC10929137

111. Rossi S. Studer V. Motta C. Polidoro S. Perugini J. Macchiarulo G. Giovannetti A.M. Pareja-Gutierrez L. Calò A. Colonna I. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis Neurology 2017 89 1338 1347 10.1212/WNL.0000000000004411 28842450

112. Sparaco M. Lavorgna L. Bonavita S. Psychiatric disorders in multiple sclerosis J. Neurol. 2021 268 45 60 10.1007/s00415-019-09426-6 31197511

113. Andreescu C. Tudorascu D. Sheu L.K. Rangarajan A. Butters M.A. Walker S. Berta R. Desmidt T. Aizenstein H. Brain structural changes in late-life generalized anxiety disorder Psychiatry Res. Neuroimaging 2017 268 15 21 10.1016/j.pscychresns.2017.08.004 28837828 PMC5593792

114. Tranfa M. Pontillo G. Uncinate Fasciculus Disruption and Anxiety in Multiple Sclerosis JAMA Netw. Open 2025 8 e254760 10.1001/jamanetworkopen.2025.4760 40227689

115. Riccelli R. Passamonti L. Cerasa A. Nigro S. Cavalli S.M. Chiriaco C. Valentino P. Nisticò R. Quattrone A. Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients Mult. Scler. J. 2016 22 1094 1105 10.1177/1352458515606987 26453680

116. Ashton K. Fuchs T.A. Oship D. Zivadinov R. Jakimovski D. Bergsland N. Ramasamy D.P. Vaughn C. Weinstock-Guttman B. Benedict R.H.B. Diagnosis of depression in multiple sclerosis is predicted by frontal–parietal white matter tract disruption J. Neurol. 2021 268 169 177 10.1007/s00415-020-10110-3 32754832